Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FMS 
Fresenius Medical Care Corporation (FMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: FMS (1-star) is a SELL. SELL since 5 days. Profits (11.65%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.67
1 Year Target Price $31.67
| 1 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.44% | Avg. Invested days 32 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 16.57B USD | Price to earnings Ratio 22.93 | 1Y Target Price 31.67 |
Price to earnings Ratio 22.93 | 1Y Target Price 31.67 | ||
Volume (30-day avg) 6 | Beta 0.85 | 52 Weeks Range 17.45 - 29.71 | Updated Date 06/30/2025 |
52 Weeks Range 17.45 - 29.71 | Updated Date 06/30/2025 | ||
Dividends yield (FY) 2.79% | Basic EPS (TTM) 1.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.17% | Operating Margin (TTM) 7.82% |
Management Effectiveness
Return on Assets (TTM) 2.91% | Return on Equity (TTM) 5.3% |
Valuation
Trailing PE 22.93 | Forward PE 12.38 | Enterprise Value 27467672892 | Price to Sales(TTM) 0.85 |
Enterprise Value 27467672892 | Price to Sales(TTM) 0.85 | ||
Enterprise Value to Revenue 1.21 | Enterprise Value to EBITDA 7.4 | Shares Outstanding 586827008 | Shares Floating 209464927 |
Shares Outstanding 586827008 | Shares Floating 209464927 | ||
Percent Insiders - | Percent Institutions 7.68 |
Analyst Ratings
Rating 3 | Target Price 31.67 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 4 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Fresenius Medical Care Corporation
Company Overview
History and Background
Fresenius Medical Care was founded in 1996 through the merger of Fresenius AG's dialysis division and National Medical Care, Inc. It has grown to become the world's largest provider of dialysis products and services.
Core Business Areas
- Dialysis Services: Provides dialysis treatment and related services to patients with chronic kidney failure through a network of dialysis clinics.
- Dialysis Products: Develops, manufactures, and distributes a wide range of products for dialysis treatment, including dialysis machines, dialyzers, and related disposables.
- Care Coordination: Offers care coordination services to manage patient health and improve outcomes.
- Acute Care Therapies: Provides products for acute and chronic extracorporeal therapies
Leadership and Structure
The company is led by a Management Board. The organizational structure includes regional and functional divisions responsible for specific business areas.
Top Products and Market Share
Key Offerings
- Dialysis Machines (4008S, 5008S): These machines are used for hemodialysis. Fresenius is a leading provider in this market, competing with Baxter (BAX) and Nikkiso. Market share data is complex due to varying regional strengths and specific machine models.
- Dialyzers (FX CorDiax series): Dialyzers filter waste and excess fluid from the blood. Competitors include Asahi Kasei and Nipro. Similar to dialysis machines, precise global market share data is fragmented.
- Dialysis Clinics: A global network providing in-center and home dialysis. Competitors include DaVita (DVA) and U.S. Renal Care. Specific revenue from clinics is a large part of total revenue and varies by region. No single source for number of users.
Market Dynamics
Industry Overview
The dialysis industry is characterized by increasing prevalence of chronic kidney disease (CKD), driven by factors such as diabetes and hypertension. It's a highly regulated industry.
Positioning
Fresenius Medical Care is the largest player globally in the dialysis market, benefiting from its scale, integrated product and service offerings, and established relationships with healthcare providers. Competitive advantages include their brand recognition and vertically integrated business model.
Total Addressable Market (TAM)
The global dialysis market is estimated to be around $95 billion. Fresenius Medical Care holds a significant portion of this TAM due to its global footprint and comprehensive product/service portfolio.
Upturn SWOT Analysis
Strengths
- Global market leader
- Integrated product and service offerings
- Extensive dialysis clinic network
- Strong brand recognition
- Vertical Integrated Business Model
Weaknesses
- High debt levels
- Exposure to regulatory changes and reimbursement pressures
- Operational inefficiencies
- Dependence on dialysis treatment revenue
Opportunities
- Expanding dialysis services in emerging markets
- Developing innovative dialysis technologies
- Growing home dialysis market
- Focus on preventative care to delay the need for dialysis
Threats
- Increasing competition from other dialysis providers
- Price erosion due to reimbursement cuts
- Technological disruptions
- Adverse currency exchange rates
Competitors and Market Share
Key Competitors
- DVA
- BAX
- NXTM
Competitive Landscape
Fresenius Medical Care competes primarily with DaVita in the dialysis services market. It faces competition from Baxter and other medical device companies in the dialysis products market. Its scale and global presence provide a competitive advantage.
Major Acquisitions
NxStage Medical
- Year: 2019
- Acquisition Price (USD millions): 2000
- Strategic Rationale: Expanded Fresenius' presence in the home dialysis market and broadened its product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is linked to the growth of the global dialysis market.
Future Projections: Future growth is projected to be driven by the increasing prevalence of CKD and expanding access to dialysis treatment in emerging markets. Analyst expectations vary based on company strategy and market conditions.
Recent Initiatives: Recent initiatives include expanding home dialysis offerings and investing in digital health solutions for care coordination.
Summary
Fresenius Medical Care is a global leader in the dialysis market, leveraging its scale and integrated business model. While facing regulatory pressures and competition, the company benefits from the increasing prevalence of chronic kidney disease. Expanding into home dialysis and emerging markets presents opportunities for future growth. Investors should monitor reimbursement rates and competitive dynamics closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
- Market research reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is based on available estimates and may not be precise. Financial information is based on publicly available data, which may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fresenius Medical Care Corporation
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-09-19 | Chair of Management Board & CEO Ms. Helen Giza | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 112035 | |
Full time employees 112035 | |||
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.